Dr. Li co-founded ADARx and has over two decades of pharmaceutical and biotech research and development experience. At Arrowhead Pharmaceuticals, Dr. Li led delivery platform and product candidate development; at Merck, Dr. Li led an siRNA development team.
ADARx uses its siRNA drug development experience and proprietary technologies to develop next-generation siRNA therapeutics for a broad spectrum of diseases.
ADARx Pharmaceuticals, Inc. and its subsidiaries describe their practices for collecting, using, and disclosing personal information, including through the Site and social media pages.
Crunchbase reports that North American startups raise $92 billion in Q3 2026, down 35% from the prior quarter but up 50% year over year. The decline largely reflects the absence of new megafinancings for OpenAI and Anthropic, while AI-focused companies still receive $61 billion. Nvidia’s $12.93 billion acquisition of Hugging Face leads robust M&A, while 17 venture-backed companies go public and raise just under $4 billion.
